董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Ferrari | 男 | Executive Chairman of the Board | 69 | 23.50万美元 | 未持股 | 2023-05-26 |
| Branislav Vajdic | 男 | Chief Executive Officer, Director | 69 | 101.94万美元 | 未持股 | 2023-05-26 |
| Willem Elfrink | 男 | Director,Chairman of the Board | 71 | 13.50万美元 | 未持股 | 2023-05-26 |
| George A. de Urioste | 男 | Director | 67 | 16.00万美元 | 未持股 | 2023-05-26 |
| Marga Ortigas Wedekind | 女 | Director | 61 | 14.00万美元 | 未持股 | 2023-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Branislav Vajdic | 男 | Chief Executive Officer, Director | 69 | 101.94万美元 | 未持股 | 2023-05-26 |
| Richard Brounstein | 男 | Chief Financial Officer | 73 | 41.57万美元 | 未持股 | 2023-05-26 |
董事简历
中英对照 | 中文 | 英文- Richard Ferrari
-
Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
Richard Ferrari,is the Co-Founder of De Novo Ventures, a healthcare investment firm dedicated to medical devices and bio-technology, and has served as a Managing Director since 2000. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum. From October 1995 to May 1999, Mr. Ferrari co-founded and served as the Chief Executive Officer of CardioThoracic Systems, Inc., a manufacturer of products and systems for minimally invasive cardiac surgery. From January 1990 to June 1995, Mr. Ferrari served as the CEO of Cardiovascular Imaging Systems, a developer of ultrasound imaging. Mr. Ferrari has served on the board of directors of HeartBeam, Inc. since December 2019 and as Executive Chairman since June 2021. Mr. Ferrari also serves as the Executive Chairman and a member of the board of directors of Tenon Medical, Inc. Mr. Ferrari is Executive Chairman of the Board for Retriever Medical Inc.; Vice Chairman of the Board for Advanced Bifurcation Systems Inc.; and a board member of several other private medical device companies. Mr. Ferrari holds a B.S. from Ashland University and an M.B.A. from the University of South Florida. - Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
- Richard Ferrari,is the Co-Founder of De Novo Ventures, a healthcare investment firm dedicated to medical devices and bio-technology, and has served as a Managing Director since 2000. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum. From October 1995 to May 1999, Mr. Ferrari co-founded and served as the Chief Executive Officer of CardioThoracic Systems, Inc., a manufacturer of products and systems for minimally invasive cardiac surgery. From January 1990 to June 1995, Mr. Ferrari served as the CEO of Cardiovascular Imaging Systems, a developer of ultrasound imaging. Mr. Ferrari has served on the board of directors of HeartBeam, Inc. since December 2019 and as Executive Chairman since June 2021. Mr. Ferrari also serves as the Executive Chairman and a member of the board of directors of Tenon Medical, Inc. Mr. Ferrari is Executive Chairman of the Board for Retriever Medical Inc.; Vice Chairman of the Board for Advanced Bifurcation Systems Inc.; and a board member of several other private medical device companies. Mr. Ferrari holds a B.S. from Ashland University and an M.B.A. from the University of South Florida.
- Branislav Vajdic
-
Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
Branislav Vajdic,Chief Executive Officer and Founder of HeartBeam, Inc. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices as well as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota. - Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
- Branislav Vajdic,Chief Executive Officer and Founder of HeartBeam, Inc. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices as well as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.
- Willem Elfrink
-
自我们成立以来，Willem Elfrink一直担任董事会主席，并于2021年6月辞去该职位，但仍是董事会成员。Elfrink先生在将新技术引入市场方面拥有超过40年的经验。Elfrink先生通过董事会参与，战略营销，治理和资本结构积极为投资组合公司做出贡献。Elfrink先生也是WPE Ventures Digitized Solutions（一家安全和数字化解决方案投资公司）的创始人兼总裁。Elfrink先生于1997年加入Cisco，并于2000年至2006年和2007年至2015年分别担任Cisco的行业解决方案执行副总裁和首席全球化官，在此Elfrink先生为公司的关键战略和运营决策做出了贡献。他被广泛认为是思科的常驻企业企业家，他的全球章程是确定重要的技术机会。Elfrink还领导了一个名为物联网世界论坛IOTWF的行业倡议。在加入Cisco之前，Elfrink先生在Olivetti，Xerox，HP，Digital Equipment Corporation和Philips担任管理和高级管理职位。Elfrink先生在荷兰鹿特丹的理工学院获得了工程学士学位。
Willem Elfrink,was Chairman of the Board since Heartbeam, Inc. founding and in June 2021 stepped down from this position but remains a Board member. Mr. Elfrink is also the Founder and President of WPE Ventures Digitized Solutions, a security and digitization solutions investment firm. Mr. Elfrink joined Cisco in 1997 and was Cisco's Executive Vice President of Industry Solutions and Chief Globalization Officer from 2000 to 2006 and 2007 to 2015 respectively, where Mr. Elfrink made and contributed to key strategic and operational decisions of the Company. Widely recognized as Cisco's Corporate Entrepreneur in residence, his global charter was to identify significant technology opportunities. Mr. Elfrink also led an industry initiative — called the Internet of Things World Forum. Before joining Cisco, Mr. Elfrink held management and senior management positions at Olivetti, Xerox, HP, Digital Equipment Corporation and Philips. Mr. Elfrink earned a Bachelor of Engineering degree from the Institute of Technology in Rotterdam, the Netherlands. - 自我们成立以来，Willem Elfrink一直担任董事会主席，并于2021年6月辞去该职位，但仍是董事会成员。Elfrink先生在将新技术引入市场方面拥有超过40年的经验。Elfrink先生通过董事会参与，战略营销，治理和资本结构积极为投资组合公司做出贡献。Elfrink先生也是WPE Ventures Digitized Solutions（一家安全和数字化解决方案投资公司）的创始人兼总裁。Elfrink先生于1997年加入Cisco，并于2000年至2006年和2007年至2015年分别担任Cisco的行业解决方案执行副总裁和首席全球化官，在此Elfrink先生为公司的关键战略和运营决策做出了贡献。他被广泛认为是思科的常驻企业企业家，他的全球章程是确定重要的技术机会。Elfrink还领导了一个名为物联网世界论坛IOTWF的行业倡议。在加入Cisco之前，Elfrink先生在Olivetti，Xerox，HP，Digital Equipment Corporation和Philips担任管理和高级管理职位。Elfrink先生在荷兰鹿特丹的理工学院获得了工程学士学位。
- Willem Elfrink,was Chairman of the Board since Heartbeam, Inc. founding and in June 2021 stepped down from this position but remains a Board member. Mr. Elfrink is also the Founder and President of WPE Ventures Digitized Solutions, a security and digitization solutions investment firm. Mr. Elfrink joined Cisco in 1997 and was Cisco's Executive Vice President of Industry Solutions and Chief Globalization Officer from 2000 to 2006 and 2007 to 2015 respectively, where Mr. Elfrink made and contributed to key strategic and operational decisions of the Company. Widely recognized as Cisco's Corporate Entrepreneur in residence, his global charter was to identify significant technology opportunities. Mr. Elfrink also led an industry initiative — called the Internet of Things World Forum. Before joining Cisco, Mr. Elfrink held management and senior management positions at Olivetti, Xerox, HP, Digital Equipment Corporation and Philips. Mr. Elfrink earned a Bachelor of Engineering degree from the Institute of Technology in Rotterdam, the Netherlands.
- George A. de Urioste
-
George A. de Urioste，结合了30多年的经验，在高科技行业的高级管理。此前，他曾参与10多家公司，担任多种职务，包括董事会董事、首席运营官和首席财务官。从1992年到1998年，他担任Remedy Corporation Software的首席财务官，从2000年到2003年，他担任Aeroprise，Inc.（软件）的首席执行官，从2004年到2006年，他担任Chordiant Software的首席运营官兼首席财务官，他于2008年担任Marvell Technology，Inc.（半导体公司）的临时首席运营官兼首席财务官。从2014年到2018年，他担任Pluribus Networks，Inc.（软件）的首席财务官。从2019年到2020年，他担任4IQ，Inc.（软件）的首席财务官，目前是Mozilla，Inc.（软件）的临时首席财务官。De Urioste的董事经验包括以下公司的审计委员会主席职位:Rainmaker Systems, Inc.（业务外包），从2003年到2005年，Saba Software, Inc.（软件）从2008年到2010年，GCT，Inc.（半导体），从2009年到2011年，Villa Montalvo（表演艺术中心），从2011年到2013年，Bridgelux，该公司于2011年至2016年（LED照明）和Vendavo，Inc.于2013年至2014年（软件）。他也曾担任Aeroprise，Inc.（软件）的董事会主席（从2000年到2005年）。他目前是Silicon Valley Directors Exchange（董事会教育活动的非营利组织）的董事会董事。他拥有南加州大学的本科学位和加州大学伯克利分校的工商管理硕士学位。De Urioste先生也是加利福尼亚州的注册会计师（不活跃）。
George A. de Urioste,combines over 30 years of experience in high technology industry senior management. Previously, Mr. de Urioste has been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. Mr. de Urioste was Chief Financial Officer of Remedy Corporation (software) from 1992 to 1998, Chief Executive Officer of Aeroprise, Inc., from 2000 to 2003 (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software), interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc. (semiconductors) during 2008, Chief Financial Officer for Pluribus Networks, Inc. (software) 2014 to 2018, Chief Financial Officer for 4iQ, Inc. (software) 2019 to 2020 and interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste's Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (business outsourcing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). Mr. de Urioste was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). Mr. de Urioste is currently a Board Director at Silicon Valley Directors Exchange, (a not-for-profit for Board education events). Mr. de Urioste has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California and is a member of the Latino Corporate Directors Association. - George A. de Urioste，结合了30多年的经验，在高科技行业的高级管理。此前，他曾参与10多家公司，担任多种职务，包括董事会董事、首席运营官和首席财务官。从1992年到1998年，他担任Remedy Corporation Software的首席财务官，从2000年到2003年，他担任Aeroprise，Inc.（软件）的首席执行官，从2004年到2006年，他担任Chordiant Software的首席运营官兼首席财务官，他于2008年担任Marvell Technology，Inc.（半导体公司）的临时首席运营官兼首席财务官。从2014年到2018年，他担任Pluribus Networks，Inc.（软件）的首席财务官。从2019年到2020年，他担任4IQ，Inc.（软件）的首席财务官，目前是Mozilla，Inc.（软件）的临时首席财务官。De Urioste的董事经验包括以下公司的审计委员会主席职位:Rainmaker Systems, Inc.（业务外包），从2003年到2005年，Saba Software, Inc.（软件）从2008年到2010年，GCT，Inc.（半导体），从2009年到2011年，Villa Montalvo（表演艺术中心），从2011年到2013年，Bridgelux，该公司于2011年至2016年（LED照明）和Vendavo，Inc.于2013年至2014年（软件）。他也曾担任Aeroprise，Inc.（软件）的董事会主席（从2000年到2005年）。他目前是Silicon Valley Directors Exchange（董事会教育活动的非营利组织）的董事会董事。他拥有南加州大学的本科学位和加州大学伯克利分校的工商管理硕士学位。De Urioste先生也是加利福尼亚州的注册会计师（不活跃）。
- George A. de Urioste,combines over 30 years of experience in high technology industry senior management. Previously, Mr. de Urioste has been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. Mr. de Urioste was Chief Financial Officer of Remedy Corporation (software) from 1992 to 1998, Chief Executive Officer of Aeroprise, Inc., from 2000 to 2003 (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software), interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc. (semiconductors) during 2008, Chief Financial Officer for Pluribus Networks, Inc. (software) 2014 to 2018, Chief Financial Officer for 4iQ, Inc. (software) 2019 to 2020 and interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste's Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (business outsourcing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). Mr. de Urioste was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). Mr. de Urioste is currently a Board Director at Silicon Valley Directors Exchange, (a not-for-profit for Board education events). Mr. de Urioste has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California and is a member of the Latino Corporate Directors Association.
- Marga Ortigas Wedekind
-
Marga Ortigas Wedekind，2009年1月，她加入Omnicell并担任副总裁负责市场营销。2009年5月，她被任命为副总裁负责全球营销和产品开发。2012年3月，她被任命为副总裁负责全球营销和产品开发。从2002年2月到2008年10月，她担任Xoft, Inc.（一个医疗设备公司）的高级副总裁负责营销、开发、和临床事务 。她早期担任几个高级市场营销职务，包括从1990年1月到2000年2月，她在Guidant Corporation的血管介入部门任职，负责国际和全球销售和市场营销，最终担任其董事负责市场发展。她持有威尔斯利学院（Wellesley College）的政治经济学学士学位，以及斯坦福大学商学院（Stanford Graduate School of Business ）的工商管理硕士学位。
Marga Ortigas Wedekind,has been Chief Commercial Strategy Officer of Fogarty Innovation, a non-profit educational incubator for early stage medtech companies since December 2019, Executive Vice President of Marketing and Payer Relations for iRhythm Technologies Inc., a publicly-traded digital healthcare company from July 2015 through July 2019, Executive Vice President, Global Marketing and Product Development of Omnicell Inc., a publicly-traded developer of automated medication dispensing and analytics systems where she led the Marketing, International and Engineering departments from 2009 to 2015, Senior Vice President, Marketing, Development, and Clinical Affairs at Xoft, Inc, a developer of disruptive technology to deliver radiation therapy with capital equipment and high-end disposables from 2002 to December 2008. She started her medtech career at Guidant Vascular, now Abbott Vascular. Ms. Ortigas-Wedekind was on the board of Itamar Medical (NASDAQ: ITMR), which provides digitally-enabled systems for sleep apnea management until its sale to Zoll Medical in December 2021, Total Flow Cannula, an early stage company developing a mechanism to improve safety during on-pump open heart surgery and, the Bay Area Cancer Coalition, a non-profit organization that supports those affected by breast or ovarian cancer. Ms. Ortigas-Wedekind is a limited partner and advisory board member for Launchpad Digital Health, a venture fund focused on digital heath technologies and is also an angel investor with Health Tech Capital. Ms. Ortigas-Wedekind has an undergraduate degree from Wellesley College and an MBA from the Stanford Graduate School of Business. - Marga Ortigas Wedekind，2009年1月，她加入Omnicell并担任副总裁负责市场营销。2009年5月，她被任命为副总裁负责全球营销和产品开发。2012年3月，她被任命为副总裁负责全球营销和产品开发。从2002年2月到2008年10月，她担任Xoft, Inc.（一个医疗设备公司）的高级副总裁负责营销、开发、和临床事务 。她早期担任几个高级市场营销职务，包括从1990年1月到2000年2月，她在Guidant Corporation的血管介入部门任职，负责国际和全球销售和市场营销，最终担任其董事负责市场发展。她持有威尔斯利学院（Wellesley College）的政治经济学学士学位，以及斯坦福大学商学院（Stanford Graduate School of Business ）的工商管理硕士学位。
- Marga Ortigas Wedekind,has been Chief Commercial Strategy Officer of Fogarty Innovation, a non-profit educational incubator for early stage medtech companies since December 2019, Executive Vice President of Marketing and Payer Relations for iRhythm Technologies Inc., a publicly-traded digital healthcare company from July 2015 through July 2019, Executive Vice President, Global Marketing and Product Development of Omnicell Inc., a publicly-traded developer of automated medication dispensing and analytics systems where she led the Marketing, International and Engineering departments from 2009 to 2015, Senior Vice President, Marketing, Development, and Clinical Affairs at Xoft, Inc, a developer of disruptive technology to deliver radiation therapy with capital equipment and high-end disposables from 2002 to December 2008. She started her medtech career at Guidant Vascular, now Abbott Vascular. Ms. Ortigas-Wedekind was on the board of Itamar Medical (NASDAQ: ITMR), which provides digitally-enabled systems for sleep apnea management until its sale to Zoll Medical in December 2021, Total Flow Cannula, an early stage company developing a mechanism to improve safety during on-pump open heart surgery and, the Bay Area Cancer Coalition, a non-profit organization that supports those affected by breast or ovarian cancer. Ms. Ortigas-Wedekind is a limited partner and advisory board member for Launchpad Digital Health, a venture fund focused on digital heath technologies and is also an angel investor with Health Tech Capital. Ms. Ortigas-Wedekind has an undergraduate degree from Wellesley College and an MBA from the Stanford Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Branislav Vajdic
Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
Branislav Vajdic,Chief Executive Officer and Founder of HeartBeam, Inc. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices as well as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.- Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
- Branislav Vajdic,Chief Executive Officer and Founder of HeartBeam, Inc. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices as well as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.
- Richard Brounstein
Richard Brounstein，首席财务官，拥有超过30年的医疗技术高级管理经验。自2017年以来，布朗斯坦先生一直是金融服务公司Hardesty，LLC的合伙人，目前是该公司的合伙人，布朗斯坦先生目前是CTRLCFO，LLC的董事总经理，CTRLCFO，LLC是布朗斯坦先生于2016年成立的公司，旨在支持生命科学和技术领域的初创企业。此前，从2008年到2011年，Brounstein先生担任NewCardio，Inc.的兼职首席财务官兼秘书，这是一家心脏病学领域的微型上市公司，在他的职业生涯中，他在生命科学或技术领域的其他9家公司任职，担任过首席财务官等职位，首席运营官，财务主管和会计经理。从2001年6月到2007年11月，Brounstein先生在Calypte Biomedical Corporation（一家公开上市的医疗设备公司）担任多个职位，包括首席财务官和执行副总裁。布朗斯坦先生于2012年至2018年担任CIMR加州医学研究所的董事会成员。自2000年以来，Brounstein先生一直在Financial Executives International的硅谷分部的董事会任职。2007年1月，Brounstein先生被任命为2007COSO监测项目的国家成员代表，该委员会于2009年2月发布了监测内部财务控制的新准则；随后，Brounstein先生是FEI工作队的成员，该工作队于2013年发布了COSO内部控制框架的最新版本。2005年3月，被任命为SEC小型上市公司咨询委员会成员。Brounstein先生在安达信会计师事务所（Arthur Andersen LLP，以前是一家公共会计师事务所）工作时获得了注册会计师证书。Brounstein先生拥有密歇根州立大学的会计学学士学位和金融学工商管理硕士学位。
Richard Brounstein,Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017 Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. Previously, from 2008 to 2011 Mr. Brounstein was Chief Financial Officer and Secretary on a part-time basis of NewCardio, Inc., a microcap public company in the Cardiology space, and over his career has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007 Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. Mr. Brounstein served on the Board of CIMR California Institute of Medical Research from 2012 to 2018. Since 2000 Mr. Brounstein has been on the Board of Financial Executives International (FEI)'s Silicon Valley Chapter. In January 2007 Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005 Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.- Richard Brounstein，首席财务官，拥有超过30年的医疗技术高级管理经验。自2017年以来，布朗斯坦先生一直是金融服务公司Hardesty，LLC的合伙人，目前是该公司的合伙人，布朗斯坦先生目前是CTRLCFO，LLC的董事总经理，CTRLCFO，LLC是布朗斯坦先生于2016年成立的公司，旨在支持生命科学和技术领域的初创企业。此前，从2008年到2011年，Brounstein先生担任NewCardio，Inc.的兼职首席财务官兼秘书，这是一家心脏病学领域的微型上市公司，在他的职业生涯中，他在生命科学或技术领域的其他9家公司任职，担任过首席财务官等职位，首席运营官，财务主管和会计经理。从2001年6月到2007年11月，Brounstein先生在Calypte Biomedical Corporation（一家公开上市的医疗设备公司）担任多个职位，包括首席财务官和执行副总裁。布朗斯坦先生于2012年至2018年担任CIMR加州医学研究所的董事会成员。自2000年以来，Brounstein先生一直在Financial Executives International的硅谷分部的董事会任职。2007年1月，Brounstein先生被任命为2007COSO监测项目的国家成员代表，该委员会于2009年2月发布了监测内部财务控制的新准则；随后，Brounstein先生是FEI工作队的成员，该工作队于2013年发布了COSO内部控制框架的最新版本。2005年3月，被任命为SEC小型上市公司咨询委员会成员。Brounstein先生在安达信会计师事务所（Arthur Andersen LLP，以前是一家公共会计师事务所）工作时获得了注册会计师证书。Brounstein先生拥有密歇根州立大学的会计学学士学位和金融学工商管理硕士学位。
- Richard Brounstein,Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017 Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. Previously, from 2008 to 2011 Mr. Brounstein was Chief Financial Officer and Secretary on a part-time basis of NewCardio, Inc., a microcap public company in the Cardiology space, and over his career has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007 Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. Mr. Brounstein served on the Board of CIMR California Institute of Medical Research from 2012 to 2018. Since 2000 Mr. Brounstein has been on the Board of Financial Executives International (FEI)'s Silicon Valley Chapter. In January 2007 Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005 Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.